Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY January 2024 slide deck - over 120 panc pts studied

<< Previous

Bullboard Posts

Next >>

Comment by 13X2413on Feb 01, 2024 3:03pm

120 Views

Post# 35857826

RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

I appreciate your efforts in trying to prop this baby up as much as possible. It's not working. The people that follow this board don't have enough pull to affect the share price either way.
We need some kind of positive action from company. They don't seem to have concerns about the price tanking at a steady pace. Pretty disappointing.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec